摘要
替诺福韦酯是2014年在我国正式上市用于慢性乙型肝炎的抗病毒治疗的核苷类新药,应用以来其肾损害的副作用引起较多关注,本文就替诺福韦酯的的副作用、肾脏损害特点和机制、临床表现、临床对策等方面进行一综述,为本药的临床应用提供借鉴参考。
As a new nucleoside drug for chronic hepatitis B antiviral Treatment,Tenofovir Disoproxil Fumarate was officially listed in China in 2014.The side effects of renal damage have attracted more attention since its wide application.In this systematic review,side effects of Tenofovir Disoproxil Fumarate,the characteristics and mechanism of renal injury,the clinical manifestations,and the clinical treatment will be mainly discussed.
引文
[1]李金金,袁有斌.乙肝病毒载量与原发性肝癌的关系[J].中医临床研究,2014,6(7):136-138.
[2]潘爱欢,郭锐华,老成康.阿德福韦酯和拉米夫定联合治疗肝炎后肝硬化的效果及安全性分析[J].中国当代医药,2017,24(15):79-81.
[3]Lamorde M,Byakika-Kibwika P,Tamale WS,et al.Effect of food on the steady-state pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan adults[J].AIDS Res Treat,2012,2012:105980.
[4]Kitrinos KM,Corsa A,Liu Y,et al.No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B[J].Hepatology,2014,59:434-442.
[5]王霞,孙怡,郑永红.核苷类似物在慢性乙型肝炎抗病毒治疗中的效果评价[J].山西医药杂志,2013,42(6):644-647.
[6]葛瑛,李德明,范韫明.替诺福韦酯对抗病毒治疗病毒学应答不佳的慢性乙型肝炎患者疗效[J].中华内科杂志,2014,53(9):697-700.
[7]黄明星,李新华,吴元凯.替诺福韦单独与联合其他核苷类似物治疗慢性乙型肝炎患者72周疗效比较[J].中山大学学报(医学科学版),2014,35(4):520-524.
[8]European Association for the Study of the Liver,european Association for the Study of the Liver.EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J].J Hepatol,2017,67(2):370-398.
[9]Fontana RJ.Side Effects of long—term oral antiviral therapyforhepatitis B[J].Hepotolgy,2009,49(5 Suppl):S185-S195.
[10]方芳,刘敏,蔡晧东,等.妊娠早期核苷(酸)类药物暴露后妊娠失败的观察[J].药物不良反应杂志,2012,14(2):73-76.
[11]周豪,温晓玉.富马酸替诺福韦酯治疗ALT水平正常、HBV DNA高载量的HBe Ag阳性HBV感染者[J].临床肝胆病杂志,2014,30(5):480.
[12]Kearney BP,Flaherty JF,Shah J.Tenofovir disoproxil fumarate:clinical pharmacology and pharmacokinetics[J].Clin Phemmcokinet,2004,43(9):595-612.
[13]陶思铮,白劲松,李重熙,等.高效抗逆转录病毒治疗艾滋病患者临床毒副作用及疗效动态观察[J].中国皮肤性病学杂志,2015,29(3):267-270.
[14]李重熙,李玉叶,白劲松,等.HIV耐药患者更换二线方案治疗2年的疗效及安全性评价[J].皮肤病与性病,2017,39(2):86-89.
[15]官丽倩,张仁芳.替诺福韦酯相关性肾毒性的研究进展[J].世界临床药物,2014,35(7):444-447.
[16]Izzedine H,Kheder Elfekih R,Housset P,et al.Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syndrome in a renal transplant patient[J].AIDS,2009,23(4):544-545.
[17]Rodriguez-Novoa S,Labarga P,Barreiro P,et al.Impair-ment in kidney tubular function in patients receiv-ing tenofovir is associated with higher tenofovirplasma concentration[J].AIDS,2010,24(7):1064-1066.
[18]Rodriguez-Nóvoa S,Alvarez E,Labarga P,et al.Renal toxicity associated with tenofovir use[J].Expert Opin Drug Saf.2010,9(4):545-559.
[19]Herlitz LC,Mohan S,Stokes MB,et al.Tenofovir nephrotoxicity:Acute tubular necrosis with distinctive clinical,pathological,and mitochondrial abnormalities[J].Kidney Int.2010,78(11):1171-7.
[20]Duarte-Rojo A,Heathcote EJ.Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B[J].Therap Adv Gastroenterol,2010,3(2):107-119.
[21]顾欣.替诺福韦与非甾体抗炎药联用可能引起急性肾功能衰竭[J].中国处方药,2006(5):69-69.
[22]李虹,李超锋,刘春礼,等.替诺福韦对肾脏功能的影响[J].临床医学,2013,33(8):57-58.
[23]陈勇华,曹群奋,洪琼怿.替诺福韦酯治疗对慢性乙型肝炎患者血清FGF-23、β2-MG、Cys-C及RBP水平的影响[J].中国临床药理学与治疗学.2017,22(7):799-804.
[24]Petersen J,Buti M.Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs[J].Expert Rev Gastroenterol Hepatol,2012,6(6):683-693.
[25]王文茜,潘国洪,伍三兰.替诺福韦致范可尼综合征文献病例分析[J].药物不良反应杂志,2017,19(4):267-271.